![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 62.50 | 60.00 | 65.00 | 62.50 | 62.50 | 62.50 | 168 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -2.86 | 8.33M |
TIDMFDBK
RNS Number : 5406G
Feedback PLC
23 November 2015
23 November 2015
Feedback plc
("Feedback" or the "Company")
TexRAD Update
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce that it has signed a Memorandum of Understanding with Alliance Medical Group ("Alliance") with the intention of integrating Feedback's TexRAD texture analysis software into Alliance's lung cancer imaging service. Although the technical discussions are at a very early stage, this is considered by Feedback to be potentially of great significance as regards the future commercialization of TexRAD software. Alliance and Feedback plan to undertake a multi-centre imaging research study to assess the use of TexRAD in lung cancer, with the eventual aim of gaining National Institute for Health and Care Excellence ("NICE") approval for TexRAD to be used in the Lung Cancer pathway. An update on the progress of the technical discussions will be provided with Feedback's interim results announcement in February 2016.
In January 2015, NHS England selected a collaborative network led by Alliance to provide PET-CT scanning services across 30 locations in England following a competitive tender process. By December 2015 Alliance and its partners in the network will be providing a substantial amount of PET-CT imaging service in England. Published research studies have suggested that assessing patients already diagnosed with lung cancer by using TexRAD texture analysis software applied on the staging PET-CT imaging examination could potentially be a major application for TexRAD and provide valuable information to clinicians. In April 2015, Feedback announced a clinical adoption study was being commenced to assess the potential for TexRAD's use in a multi-disciplinary team setting specifically focused on non-small cell lung cancer. This was followed in October 2015 by the announcement that the research arm of NHS England had 'alerted' on the potential application of TexRAD in assessing patients with lung cancer.
Dr. Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc commented:
"We are delighted to be working with Alliance who are Europe's leading independent provider of imaging services. The planned research study in lung cancer will be an important step towards the future commercialization of TexRAD."
Charles Niehaus, Group CMO, COO, Alliance Medical Group commented:
"Alliance and clinicians of the Collaborative Network are excited to be working with Feedback Plc to integrate the TexRAD software within Alliance's lung cancer service across the imaging network. We anticipate this will enhance lung cancer diagnosis and prognosis within the NHS leading to improved patient management and valuable information for both Alliance and Feedback."
For further information contact:
Feedback plc Tel: 01954 718072 Trevor Brown / Tom Charlton / Balaji Ganeshan Sanlam Securities UK (Nominated Tel: 020 7628 Adviser and Joint Broker) 2200 Simon Clements / Virginia Bull Peterhouse Corporate Finance Ltd Tel: 020 7469 (Joint Broker) 0936 Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than is readily visible to the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging Biomarker') in confident decision-making: it has the potential to assess the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCQLLFLEFFLFBQ
(END) Dow Jones Newswires
November 23, 2015 02:00 ET (07:00 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions